MX2016015350A - 1h-1,8-naftiridin-2-onas como compuestos anti-proliferativos. - Google Patents

1h-1,8-naftiridin-2-onas como compuestos anti-proliferativos.

Info

Publication number
MX2016015350A
MX2016015350A MX2016015350A MX2016015350A MX2016015350A MX 2016015350 A MX2016015350 A MX 2016015350A MX 2016015350 A MX2016015350 A MX 2016015350A MX 2016015350 A MX2016015350 A MX 2016015350A MX 2016015350 A MX2016015350 A MX 2016015350A
Authority
MX
Mexico
Prior art keywords
naphthyridin
2ones
anti proliferative
proliferative compounds
compounds
Prior art date
Application number
MX2016015350A
Other languages
English (en)
Inventor
Satya Bhujanga Rao Adibhatla Kali
Chowdary Nannapaneni Venkaiah
Kompella Amala
Krishna GAMPA Venugopala
Ganganamoni Srinivasulu
Reddy Sirigireddy Balakrishna
Original Assignee
Natco Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52589723&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2016015350(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Natco Pharma Ltd filed Critical Natco Pharma Ltd
Publication of MX2016015350A publication Critical patent/MX2016015350A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Abstract

La presente invención se refiere a nuevas 1H-1,8-naftiridin-2-onas antiproliferativas de la fórmula general (I) o sales de las mismas farmacéuticamente aceptables: en la cual los grupos variables son como se definen en la presente, y su preparación y uso en el tratamiento terapéutico de trastornos relacionados a la inhibición de tirosinas cinasas en animales de sangre caliente. Los compuestos pueden superar la resistencia al fármaco inducida por imatinib.
MX2016015350A 2014-06-06 2014-12-15 1h-1,8-naftiridin-2-onas como compuestos anti-proliferativos. MX2016015350A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2781CH2014 2014-06-06
PCT/IN2014/000777 WO2015186137A1 (en) 2014-06-06 2014-12-15 1h-1,8- naphthyridin-2ones as anti proliferative compounds

Publications (1)

Publication Number Publication Date
MX2016015350A true MX2016015350A (es) 2017-05-10

Family

ID=52589723

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016015350A MX2016015350A (es) 2014-06-06 2014-12-15 1h-1,8-naftiridin-2-onas como compuestos anti-proliferativos.

Country Status (18)

Country Link
US (2) US9765072B2 (es)
EP (1) EP3152205A1 (es)
JP (1) JP2017516867A (es)
KR (1) KR20170016921A (es)
CN (1) CN106573929A (es)
AP (1) AP2016009604A0 (es)
AU (1) AU2014396394A1 (es)
BR (1) BR112016028674A2 (es)
CA (1) CA2950250A1 (es)
CL (1) CL2016003102A1 (es)
EA (1) EA201692371A1 (es)
HK (1) HK1231469A1 (es)
IL (1) IL249118A0 (es)
MA (1) MA39524A1 (es)
MX (1) MX2016015350A (es)
PH (1) PH12016502432A1 (es)
SG (1) SG11201610149YA (es)
WO (1) WO2015186137A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015186137A1 (en) * 2014-06-06 2015-12-10 Natco Pharma Limited 1h-1,8- naphthyridin-2ones as anti proliferative compounds
CN107663151B (zh) * 2016-07-28 2021-11-26 江苏豪森药业集团有限公司 甲磺酸氟马替尼的中间体合成方法
WO2018068739A1 (zh) * 2016-10-13 2018-04-19 深圳市塔吉瑞生物医药有限公司 用于抑制蛋白激酶活性的炔基杂环类化合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2008008152A (es) 2005-12-23 2008-09-12 Ariad Pharma Inc Compuestos heterociclicos biciclicos.
BRPI0710328A2 (pt) * 2006-05-08 2011-08-09 Ariad Pharma Inc composto da fórmula i, um tautomer da mesma, ou um sal farmaceuticamente aceitável, hidrato ou outro solvato do mesmo e método para o tratamento de cáncer em um mamìfero necessitado do mesmo e composição
CN101490053B (zh) * 2006-05-08 2013-09-11 阿里亚德医药股份有限公司 单环杂芳基化合物
US7790756B2 (en) 2006-10-11 2010-09-07 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
EP2519517B1 (en) * 2009-12-29 2015-03-25 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
JP5676650B2 (ja) 2010-01-29 2015-02-25 ハンミ・サイエンス・カンパニー・リミテッドＨａｎｍｉ Ｓｃｉｅｎｃｅ Ｃｏ．， Ｌｔｄ． プロテインキナーゼ阻害活性を有するチエノ［３，２−ｄ］ピリミジン誘導体
WO2015186137A1 (en) * 2014-06-06 2015-12-10 Natco Pharma Limited 1h-1,8- naphthyridin-2ones as anti proliferative compounds

Also Published As

Publication number Publication date
CA2950250A1 (en) 2015-12-10
WO2015186137A1 (en) 2015-12-10
EP3152205A1 (en) 2017-04-12
AP2016009604A0 (en) 2016-12-31
US20170114057A1 (en) 2017-04-27
JP2017516867A (ja) 2017-06-22
CL2016003102A1 (es) 2017-06-23
US10047088B2 (en) 2018-08-14
SG11201610149YA (en) 2017-01-27
HK1231469A1 (zh) 2017-12-22
IL249118A0 (en) 2017-01-31
US9765072B2 (en) 2017-09-19
KR20170016921A (ko) 2017-02-14
US20170349588A1 (en) 2017-12-07
MA39524A1 (fr) 2018-01-31
EA201692371A1 (ru) 2017-04-28
BR112016028674A2 (pt) 2017-08-22
AU2014396394A1 (en) 2016-12-08
CN106573929A (zh) 2017-04-19
PH12016502432A1 (en) 2017-03-06

Similar Documents

Publication Publication Date Title
PH12018500041A1 (en) Substituted aza compoounds as irak-4 inhibitors
PH12018500040A1 (en) Indazole and azaindazole compounds as irak-4 inhibitors
MX2020012165A (es) Derivados de bencimidazol como inhibidores de tirosina cinasa erbb para el tratamiento del cancer.
MD4800B1 (ro) Compuşi de aminopirimidinil ca inhibitori de JAK
PH12016501394A1 (en) Compounds for treating patients with ros1 mutant cancer cells
PH12017500401A1 (en) Therapeutic compounds as inhibitors of the orexin-1 receptor
UA117830C2 (uk) Похідні біпіразолу як інгібітори jak
EA201590930A1 (ru) Лекарственные формы руксолитиниба с замедленным высвобождением
WO2016109217A3 (en) Btk inhibitors
PH12016502353A1 (en) Pharmaceutical composition
TN2017000158A1 (en) Carbazole derivatives
TW201613577A (en) Pharmaceutical combinations
PH12016502394A1 (en) 1, 3, 4-thiadiazole compounds and their use in treating cancer
MY201535A (en) Therapeutic compounds
PH12016502432A1 (en) 1h-1,8-naphthyridin-2-ones as anti proliferative compounds
WO2015155680A3 (en) Pyrazole derivatives as dihydroorotate dehydrogenase (dhodh) inhibitors
EA201792445A1 (ru) Новые амидогетероарилароилгидразидэтины
MX2018007517A (es) Compuestos triciclicos y composiciones como inhibidores de quinasa.
WO2014138616A3 (en) Pyrazole compounds and methods of use thereof
PH12017501736A1 (en) Indole derivatives
PH12016502480A1 (en) Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases
PH12017501134A1 (en) Fumagillol derivatives
MX2017008497A (es) Nuevos compuestos heterocíclicos y su uso tanto en medicina como en cosmética.
MX2017005669A (es) Derivados de hidroxido de bencilo, preparacion de los mismos y uso terapeutico de los mismos.